Active Treatment Strategy Improves Overall Survival of Patients With Intracranial Mesenchymal Chondrosarcoma After Surgical Treatment

Abstract Intracranial mesenchymal chondrosarcoma (IMC) is a rare malignancy. We aimed to investigate the efficacy of treatment in overall survival (OS) for patients with IMC. Firstly, we retrospectively collected 9 cases from two medical centers, then screened the publications and enrolled 112 reported cases, and finally pooled these data together to analyze candidate prognostic factors for OS. For the treatment-related predictors, we defined active intervention if GTR (gross total resection) and/or radiotherapy (GaoR) was employed and inactive one when neither GTR nor radiotherapy (NGnR) was used. The 1-year, 3-year and 5-year OS for patients with IMC were 82.6%, 60.3% and 49.4%, respectively. NGnR was the independent risk factor for OS (HR [hazard ratio] = 4.70, 95% CI [confidence interval] 1.575 ~ 14.060; p = 0.006). The 1-year, 3-year and 5-year of patients with GaoR were higher than that of patients with NGnR (85.1%, 68.7% and 57.7% vs. 72.7%, 42.4% and 21.2%). Patients with IMC could obtain survival benefit from active intervention (GaoR group). GTR and/or radiotherapy should be recommended whenever feasible.